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SUMMARY
The oncogenic AKT kinase is a key regulator of apoptosis, cell growth and cell cycle progression. 
Despite its important role in proliferation, it remains largely unknown how AKT is mechanistically 
linked to cell cycle. We show here that Cyclin F, a substrate receptor F-box protein for the SCF 
family of E3 ubiquitin ligases, is a bona fide AKT substrate. Cyclin F expression oscillates 
throughout the cell cycle, a rare feature among the 69 human F-box proteins, and all of its known 
substrates are involved in proliferation. AKT phosphorylation of Cyclin F enhances its stability 
and promotes assembly into productive E3 ligase complexes. Importantly, expression of mutant 
versions of Cyclin F that cannot be phosphorylated by AKT impair cell cycle entry. Our data 
suggest that Cyclin F transmits mitogen signaling through AKT to the core cell cycle machinery. 
This discovery has potential implications for proliferative control in malignancies where AKT is 
activated.
eTOC Blurb
Choudhury et al. report that Cyclin F, an E3 ubiquitin ligase substrate receptor F-box protein, is 
phosphorylated by the oncogenic kinase AKT. Intriguingly, phosphorylation enhances Cyclin F 
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stability and promotes cell cycle entry. These data suggest that Cyclin F bridges growth factor to 
the core cell cycle machinery.
INTRODUCTION
Eukaryotic cells progress into the cell cycle in response to growth factor stimulation (Pardee, 
1974; Temin, 1971). This implies that intracellular signaling pathways communicate growth 
factor signaling to the core cell cycle machinery. While the general molecular framework of 
both growth factor signaling pathways and the core cell cycle oscillator have been well-
described, there remain few mechanistic links detailing how they are connected to one 
another. The mitogen sensing phosphatidylinositol 3-kinase (PI3K) – AKT pathway plays an 
important role in apoptotic evasion and cell growth. Moreover, PI3K-AKT pathway 
activation is a common feature in many malignancies (Manning and Toker, 2017). Despite 
the fact that AKT is commonly activated in cancer, and can promote cell cycle progression 
and transformation, very few established AKT substrates are directly linked to the cell cycle 
(Kandel et al., 2002; Manning et al., 2005; Skeen et al., 2006).
Cell cycle progression is driven by changes in the expression and subsequent degradation of 
many proteins (e.g. Cyclins). The ubiquitin proteasome system (UPS) represents the major 
mechanism of programmed protein degradation in eukaryotes and plays a vital role in cell 
cycle. Substrate specificity in the UPS is controlled by E3 ubiquitin ligases (Hershko and 
Ciechanover, 1998; Varshavsky, 2012). The Cullin-RING ligases (CRLs) represent the 
largest E3 ligase family in humans and encode several hundred unique enzymes. CRLs 
regulate the degradation of hundreds of proteins and have been implicated in all facets of 
eukaryotic biology, and particularly in proliferative control (Emanuele et al., 2011; Petroski 
and Deshaies, 2005). The CRLs rely on a CULLIN backbone that interacts simultaneously 
with substrates and E2 ubiquitin-conjugating enzymes. The CULLIN1 based CRL ligases, 
termed CRL1 or SCF (Skp1/Cul1/F-box), rely on a family of 69 substrate adaptors known as 
F-box proteins which designate targets for ubiquitylation. F-box proteins are defined by the 
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presence of an F-box domain which directly binds to the CULLIN1/Cul1 adaptor protein 
Skp1 (Bai et al., 1996; Jin et al., 2004). SCF complexes are modular in that different F-box 
proteins can interchangeably interact with Skp1. Substrate ubiquitylation by SCF complexes 
is often controlled by either post-translational modification of the substrate, which regulates 
binding to its cognate E3 ligase, or through changes in the abundance of the E3 ligase 
substrate receptor (Skaar et al., 2014; Vashisht et al., 2009; Zheng et al., 2016). However, an 
alternative mechanism for controlling substrate ubiquitylation is to regulate assembly of the 
ligase itself, as is the case for other cell cycle ubiquitin ligases (Sørensen et al., 2001; 
Zachariae, 1998). However, it is unknown if the assembly of specific CRL ligases is 
regulated to control substrate ubiquitylation.
Cyclin F is the founding member of the F-box family of SCF substrate receptors. Despite its 
name, Cyclin F is a non-canonical cyclin that is unable to bind or activate a CDK 
(D’Angiolella et al., 2013). Cyclin F is important for cell cycle progression and mouse 
development, but has few known substrates (Tetzlaff et al., 2004). However, all of the 
established Cyclin F targets are linked to cell cycle control: the RRM2 subunit of 
ribonucleotide reductase, spindle regulators Nusap1 and CP110, replication licensing factor 
Cdc6, and the DNA exonuclease Exo1 (D’Angiolella et al., 2010, 2012; Elia et al., 2015; 
Emanuele et al., 2011; Tetzlaff et al., 2004; Walter et al., 2016).
We recently demonstrated that Cyclin F is targeted for degradation during G1 phase by a cell 
cycle E3 ubiquitin ligase termed the Anaphase Promoting Complex/Cyclosome (APC/C) 
(Choudhury et al., 2016). Cdh1/Fzr1, the substrate receptor for the APC/C during G1 phase, 
is critical for mediating Cyclin F degradation. Surprisingly, we found that Cdh1 is itself a 
substrate for SCF(Cyclin F) in late G1 and during S-phase. This direct, reciprocal 
relationship between the APC/C and SCF(Cyclin F) represents an important negative 
feedback circuit regulating cell cycle progression. Interestingly, Cyclin F accumulation 
begins in late G1 when APC/C(Cdh1) is presumably still active (Choudhury et al., 2016).
How Cyclin F evades APC/C mediated degradation was unclear. We therefore sought to 
determine factors that enhance SCF(Cyclin F) dependent degradation of Cdh1 at the expense 
of the reverse reaction (i.e. APC/C dependent degradation of Cyclin F; Figure 1A). We 
considered phosphorylation of either Cyclin F or Cdh1 due to its well-established role in 
mediating protein ubiquitylation and degradation. Human Cyclin F contains two optimal 
AKT consensus motifs that are conserved evolutionarily. Moreover, AKT activity oscillates 
throughout the cell cycle and promotes cell cycle progression (Liu et al., 2014; Shtivelman 
et al., 2002; Skeen et al., 2006). Here we describe the control of Cyclin F by the oncogenic, 
cell cycle regulated kinase AKT.
RESULTS
Cyclin F is an AKT substrate
A recent report demonstrated that AKT kinase activity increases throughout the cell cycle 
(Liu et al., 2014). Consistent with this report, we found that phosphorylation of both 
threonine 308 and serine 473 in AKT, which contribute to AKT activity, oscillate during cell 
cycle progression while total AKT levels remain unchanged (Figure 1B and Supplemental 
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Figure 1A). Cyclin F contains two optimal, evolutionarily conserved AKT consensus motifs 
(RxRxxS/T) at threonine 31 and serine 577 (Figure 1C). We therefore investigated whether 
Cyclin F is an AKT substrate. We evaluated their kinase-substrate relationship based the 
following criteria: enzyme-substrate binding, in vitro and in vivo phosphorylation, and 
demonstration that the sites of modification are relevant in a biological context (Dephoure et 
al., 2013).
We expressed Myc-tagged Cyclin F (Myc-Cyclin F) and an active version of AKT1 (HA-
Myr-AKT1) in HEK-293T cells and purified AKT on anti-HA agarose (Figure 1D; cells 
were treated with proteasome inhibitor prior harvesting). We observed a strong co-
immunoprecipitation (co-IP) between Cyclin F and AKT1 under these conditions. Likewise, 
when we precipitated Myc-Cyclin F, we recovered AKT1 (Figure 3D). An endogenous 
Cyclin F pulldown performed in 293T cell extracts co-precipitated AKT, further confirming 
their interaction (Figure 1E). Next, we examined the ability of AKT1 to phosphorylate 
Cyclin F in an in vitro kinase assay. Purified Cyclin F was mixed with active, recombinant 
GST-AKT1 isolated from bacteria. Following their co-incubation, Cyclin F phosphorylation 
was analyzed by immunoblotting with an antibody which recognizes phosphorylated AKT 
consensus motifs (RxRxxpS/T; Figure 1F). Cyclin F was readily phosphorylated under these 
conditions. Likewise, HA-Myr-AKT1 phosphorylated Cyclin F in vitro as detected using 
radioactive [γ-32P] ATP (Supplementary Figure 1B). Furthermore, Cyclin F phosphorylation 
was dependent on T31 and S557, the predicted sites embedded in the two AKT consensus 
motifs in Cyclin F. A mutant version of Cyclin F harboring alanine substitutions at these 
sites (T31A, S577A; Cyclin FAA) showed no appreciable phosphorylation by AKT1 in in 
vitro kinase assays (Supplementary Figure 1B).
To establish that AKT1 phosphorylates Cyclin F in vivo, we isolated endogenous Cyclin F 
from whole cell extracts and analyzed it using an AKT phospho-motif antibody and mass 
spectrometry. First, we immuno-precipitated and stringently washed endogenous Cyclin F 
from cell extracts. Immunoblotting revealed a band corresponding to the molecular weight 
of endogenous, phosphorylated Cyclin F that reacted strongly with an AKT phospho-motif 
antibody, and this was abolished by acutely pre-treating cells with the selective, small-
molecule AKT inhibitor afuresertib/GSK2110183 (Figure 1G). Furthermore, the phospho-
motif reactive band was not present in control IgG pulldowns and was sensitive to treatment 
with lambda phosphatase (Supplemental Figure 1C and 1D).
Next, we ectopically expressed Myc-Cyclin F with or without a constitutively active form of 
AKT (HA-Myr-AKT1) in 293T cells. Cyclin F was recovered by anti-Myc IP and analyzed 
by mass spectrometry (Supplementary Figure 2A and B). Phosphorylation of S577 was 
identified in samples where AKT1 was expressed, and the modification was enriched 
relative to controls. We were unable to detect phospho-peptides corresponding to the T31 
site, likely because AKT phosphorylation sites are difficult to detect using conventional, 
trypsin-based digestion methods due to arginine residues in the vicinity of the modified 
serine or threonine. Taken together, these data demonstrate that Cyclin F is a bona fide AKT 
substrate.
Choudhury et al. Page 4
Cell Rep. Author manuscript; available in PMC 2017 October 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
AKT controls Cyclin F stability
To evaluate the importance of Cyclin F phosphorylation by AKT, we examined Cyclin F 
levels by immunoblot after depleting AKT using siRNAs. We depleted both AKT1 and 
AKT2 with siRNAs and compared them to cells treated with negative control 
oligonucleotides targeting firefly luciferase (siFF). Depletion of both AKT1 and AKT2 with 
multiple, unrelated siRNA oligonucleotides reduced the level of Cyclin F (Figure 2A). 
Consistently, expression of constitutively active HA-Myr-AKT1 significantly increased the 
abundance of Myc-Cyclin F (Figure 2B), together suggesting that Cyclin F levels are 
positively regulated by AKT. These results are consistent with observations showing that the 
stability of Cyclin F is altered by the pharmacological manipulation or altered expression of 
AKT (described below).
We examined whether AKT regulates Cyclin F stability. AKT1 and AKT2 were depleted 
from 293T cells by siRNAs and cells were treated with the protein translation inhibitor 
cycloheximide (CHX). Semi-quantitative analysis of immunoblots performed on these 
experiment indicates that in control cells (siFF), the half-life of Cyclin F was approximately 
137 minutes, consistent with prior observations (Choudhury et al., 2016; D’Angiolella et al., 
2012). Following AKT depletion the half-life of Cyclin F was reduced to ~111 minutes 
(Figure 2C and 2D). Importantly, this decrease was not due to a gross change in cell cycle 
since the abundance of Cyclin A was unchanged between control and AKT depleted cells.
Cyclin F stability was next analyzed following acute, pharmacological AKT inactivation. 
Inhibiting AKT with afuresertib for 1.5 hours prior to the addition of CHX reduced 
endogenous Cyclin F half-life by 50 minutes (Figure 2E and 2F). Cyclin A levels were 
unchanged between DMSO and AKT inhibitor treated cells, indicating that changes in 
Cyclin F stability were not the result of cell cycle arrest. We performed a similar assay, 
analyzing endogenous Cyclin F stability in U2OS cells that were first synchronized in S-
phase using an thymidine block and release protocol (Wang et al., 2017). Consistently, 
pharmacological AKT inactivation shortened Cyclin F half-life (Supplemental Figure 3A 
and B).
Finally, we examined Cyclin F stability following expression of constitutively active HA-
Myr-AKT1. Ectopic expression of AKT1 increased the abundance and stability of Myc-
Cyclin F being expressed from a heterologous promoter (Figure 2G and 2H), ruling out the 
possibility that changes in transcription account for its differential abundance and stability. 
Similarly, Cyclin A levels were unchanged between control and HA-Myr-AKT1 expressing 
cells, indicating that the cell cycle was not perturbed under these conditions. These data 
demonstrate an important role of AKT in controlling Cyclin F stability.
The ability of AKT to control Cyclin F stability (Figure 2), and to phosphorylate it on 
evolutionarily conserved consensus motifs (Figure 1), suggested that AKT might control 
Cyclin F through direct phosphorylation. We therefore compared the stability of Cyclin FWT 
and a phospho-deficient mutant version where both AKT phosphorylation sites are changed 
to alanine (T31A, S577A; Cyclin FAA). Importantly, Cyclin FAA was significantly less 
stable than Cyclin FWT (Figure 3A and 3B). Taken together, we conclude that direct AKT 
phosphorylation increases Cyclin F stability.
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The first AKT consensus motif in Cyclin F (T31) is located in the F-box domain. The F-box 
domain connects substrate receptor F-box proteins to the ubiquitin machinery through a 
direct interaction with Skp1. We used in silico modeling predictions to examine the Cyclin 
F-Skp1 interaction. We modeled a segment of the F-box domain from Cyclin F into the 
previously annotated structure of Skp1-Fbxl3 (Xing et al., 2013). This analysis suggested 
that Cyclin F phosphorylation would increase Skp1 binding by introducing electrostatic 
interactions between Skp1 and Cyclin F (Figure 3C). In accordance with the in silico 
modeling, ectopic expression of HA-Myr-AKT1 significantly enhanced Cyclin F binding to 
Skp1 by co-IP (Figure 3D). To determine if AKT1 directly enhances binding between Cyclin 
F and Skp1, we examined binding using phospho-deficient and phospho-mimetic versions of 
Cyclin F (Cyclin FAA and Cyclin FDD). Importantly, Cyclin FDD precipitated more Skp1 and 
Nedd8 modified Cul1, than Cyclin FAA (Figure 3E). This is significant since Cul1 is Nedd8 
conjugated in active SCF complexes (Duda et al., 2008; Saha and Deshaies, 2008). 
Similarly, Cyclin FDD precipitated more Skp1 than Cyclin FWT, whereas Cyclin FAA 
precipitated less Skp1 (Figure 3F). These data indicate that AKT phosphorylation of Cyclin 
F increases SKP1 binding, enhancing its assembly into productive SCF ligase complexes.
When serum is withdrawn from HCT116 colon cancer cells and then added back to re-
stimulate mitogen sensing pathways, we observed the expected increase in AKT activity, 
based on accumulation of phospho-Ser473 on AKT as well as phosphorylation of its 
substrate, GSK3β (Figure 4A). Likewise, there is a steady increase in Cyclin F abundance, 
starting as early as one hour after re-stimulation and continuing throughout a six-hour time 
course (Figure 4A). Cyclin A levels remained unchanged under these conditions, indicating 
that the transient withdrawal of serum did not interfere with the cell cycle. Consistently, 
pharmacological inhibition of signaling through the PI3K-AKT cascade for six hours with 
either LY294003 or AZD5363 (PI3K and AKT inhibitors, respectively) produced a 
significant reduction in Cyclin F protein levels (Figure 4B).
We recently demonstrated that SCF(Cyclin F) and APC/C(Cdh1) form a reciprocal circuit 
that contributes to cell cycle progression (Choudhury et al., 2016). Since AKT stabilizes 
Cyclin F and enhances its binding to Skp1-Cul1, we reasoned that AKT could modulate the 
Cyclin F-Cdh1 circuit. We first determined if AKT can enhance the degradation of Cdh1. 
Consistent with this notion, pharmacological inhibition of the PI3K-AKT cascade also 
increased Cdh1 levels (Figure 4B).
We established co-expression conditions where Cyclin F is efficiently degraded by Cdh1. 
This was achieved by co-expressing Myc-Cyclin F and FLAG-Cdh1, with the latter in 
excess (Figure 4C, lanes 1 vs 2). Remarkably, the addition of HA-Myr-AKT1 reversed the 
degradation reaction. When Cdh1, Cyclin F, and AKT1 are co-expressed (with Cdh1 in 
excess of Cyclin F), Cdh1 levels were reduced to nearly undetectable levels and Cyclin F 
was significantly increased, consistent with AKT stabilizing Cyclin F and destabilizing 
Cdh1 (Figure 4C, lanes 2 vs 4). Increasing the amount of AKT1 in this reaction further 
reduced Cdh1 levels, from very low to undetectable levels (Figure 4C, lane 4 vs 5). 
Consistently, ectopic expression of HA-Myr-AKT1 resulted in a dose-dependent degradation 
in Cdh1 (Supplemental Figure 4A).
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To confirm that AKT is inducing Cdh1 ubiquitylation, we introduced HA-Myr-AKT1 into 
cells expressing hexa-histidine tagged ubiquitin. Cells were lysed under denaturing 
conditions and ubiquitylated proteins were captured on nickel agarose and analyzed by 
immunoblot. Under these conditions, AKT1 enhanced the ubiquitylation of endogenous 
Cdh1 (Figure 4D). Finally, we analyzed Cdh1 stability in a CHX chase experiment in cells 
expressing either Cyclin FWT or the phospho-mimetic version, Cyclin FDD. Consistently, 
Cdh1 half-life was reduced from 83 minutes to 50 minutes in Cyclin FDD expressing cells 
(Supplementary Fig 4B and 4C) compared to Cyclin FWT controls. We therefore conclude 
that AKT phosphorylation of Cyclin F enhances assembly of the SCF(Cyclin F) complex 
and contributes to the ubiquitylation and degradation Cdh1.
Cyclin F phosphorylation contributes to cell cycle progression
Despite the importance of AKT in cell cycle progression, the direct cell cycle targets of 
AKT remain largely unknown (Manning and Toker, 2017; Skeen et al., 2006). Since Cyclin 
F regulates cell cycle progression, we tested the importance of its AKT dependent 
phosphorylation. We synchronized non-transformed RPE1 cells in G0/G1 by serum 
deprivation for 24 hours. After serum refeeding followed by EdU labeling (to monitor S-
phase entry), cells were fixed and stained on-plate for EdU incorporation using click-
chemistry and for DNA using Hoechst. Most cells began DNA synthesis by 18 hours, based 
on EdU labeling (Figure 5A). Consistent with our prior report, depletion of Cyclin F reduced 
S-phase entry at 18 hours after re-feeding (Figure 5B).
To confirm the importance of AKT in cell cycle entry, we synchronized cells in G0/G1, 
released them into inhibitor treated, serum containing media, and monitored the percent of 
S-phase cells at 18 hours after release. The start of DNA replication was impaired by AKT 
inhibition (Afuresertib/GSK2110183), CRL and SCF ligase inactivation (MLN4924, 
neddylation inhibitor), proteasome inhibition (bortezomib), and CDK4/6 inhibition 
(Palbociclib/PD0332991) (Supplemental Figure 5A). Similar results were obtained with a 
second AKT inhibitor (Uprosertib/GSK2141795; data not shown). Similar to the need for 
proteasome activity and cullin-RING E3 ubiquitin ligases, these data highlight the 
importance of AKT activity in promoting S-phase entry, as has been described by others 
(Skeen et al., 2006).
We next examined the role of Cyclin F phosphorylation by AKT. RPE1 cells transiently 
overexpressing Cyclin FWT, Cyclin FAA, Cyclin FDD or empty vector controls were serum 
starved and then re-fed to initiate cell cycle progression, monitoring S-phase entry by EdU 
incorporation. Immunoblots show that all three proteins were expressed at similar levels 
prior to refeeding (Figure 5C), consistent with the observations above that mitogen signaling 
is a significant determinant of Cyclin F abundance and stability. Cyclin FWT and Cyclin FDD 
enhanced the rate of S-phase entry compared to empty vector (Figure 5D and 5E). 
Significantly, S-phase entry was reduced in Cyclin FAA expressing cells, relative to Cyclin 
FWT and Cyclin FDD. This demonstrates an important cell cycle function for Cyclin F 
phosphorylation by AKT.
The above experiments show that AKT phosphorylation of Cyclin F accelerates progress 
into S-phase from a G0/G1 arrest. However, rapid cell cycle entry can ultimately reduce 
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proliferation by causing damage during DNA replication. Notably, cells lacking Cdh1 
rapidly progress through G1 phase (Choudhury et al., 2016; Sigl et al., 2009; Yuan et al., 
2014) and accumulate DNA damage, based on staining for the damage marker γH2AX, and 
consistent with prior reports (Supplemental Figure 5B) (Bassermann et al., 2008; Choudhury 
et al., 2016; Engelbert et al., 2008; Sigl et al., 2009). We therefore tested the effect of longer-
term expression of the various mutant versions of Cyclin F in HCT116 cells. Analysis of 
DNA content by flow cytometry showed that expression of Cyclin FDD decreased the 
population of G2/M cells and increased the percent of G1 cells (Supplementary Figure 5C 
and 5D). This was accompanied by the accumulation of phosphorylated RB (Supplementary 
Figure 5E). Furthermore, Cyclin FDD expressing cells accumulated phosphorylated Chk1, a 
marker of DNA damage induction (Supplementary Figure 5E). Together, these data point to 
an important role for AKT phosphorylation of Cyclin F in cell cycle progression and 
genome maintenance.
DISCUSSION
Cells mobilize intracellular signaling cascades to translate information from their 
extracellular environment into cellular responses and phenotypes. Pioneering studies 
demonstrated that cells sense the availability of nutrients, mitogens, and growth factors to 
pass through a restriction point in G1 phase and proceed into the cell cycle (Pardee, 1974; 
Zetterberg and Larsson, 1985). However, a molecular description of how cells transmit the 
presence of mitogens to the cell cycle machinery remains unclear. The most well-established 
connection between mitogen signaling pathways and the core cell cycle oscillator centers on 
the CDK4/6-RB-E2F pathway (Weinberg, 1995). In response to growth factors, cells 
upregulate transcription of Cyclin D, the activating subunit for the G1-phase CDK4/6 
kinases (Peeper et al., 1997). CDK4/6 inactivates RB, enabling E2F-dependent transcription 
of myriad cell cycle genes and coupling extracellular cues to the cell cycle. Importantly, 
cells that are deficient in Cyclin D or CDK4/6 arrest when serum is withdrawn and re-enter 
the cell cycle upon refeeding (Kozar et al., 2004; Malumbres et al., 2004). This implies that 
other molecules and pathways are involved in connecting mitogen and nutrient sensing 
pathways to the core cell cycle machinery.
The APC/C is active throughout G1 and inhibited in S-phase. APC/C inactivation prior to 
G1/S represents a so-called “commitment point” for cell cycle entry (Brandeis and Hunt, 
1996; Cappell et al., 2016). We recently showed that Cyclin F is targeted for degradation by 
the APC/C (Choudhury et al., 2016). Furthermore, we demonstrated that SCF(Cyclin F) is 
important for timely progression into S-phase due to its role in targeting Cdh1 for 
degradation in late G1 and S-phase (Choudhury et al., 2016).
Here we demonstrate that Cyclin F is a direct substrate of the oncogenic, cell cycle regulated 
kinase AKT. We show that AKT increases Cyclin F stability and enhances its assembly into 
SCF ligase complexes. The activation of AKT during the cell cycle and the consequent 
stabilization of Cyclin F do not appear precisely coordinated suggesting the AKT may 
control numerous other substrates, and that the ordering of these substrates might be highly 
regulated, as is the case for CDK targets (Swaffer et al., 2016). Our data are consistent with 
a model where AKT toggles a switch between Cyclin F-mediated Cdh1 degradation and 
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Cdh1 mediated Cyclin F degradation. APC/C(Cdh1) is a core component of the cell cycle 
oscillator due to its direct role in targeting mitotic Cyclins, among many other cell cycle 
proteins. Therefore, our data connect growth factor signaling through AKT to the core cell 
cycle oscillator via the F-box protein Cyclin F.
We propose a speculative model that a positive feedback loop, initiated by growth factor 
signaling and transmitted through AKT, helps to coordinate cell cycle progression. In this 
loop, AKT phosphorylates Cyclin F, enhancing its assembly into competent ligase 
complexes (above). SCF(Cyclin F) catalyzes the degradation of Cdh1, which otherwise 
restricts S-phase entry (Choudhury et al., 2016). With APC/C activity disabled via Cdh1 
destruction (and likely through additional mechanisms), Cyclin A accumulates and activities 
CDK2, amplifying the loop through positive feedback. This positive feedback comes from 
the ability Cyclin A-Cdk2 to activate AKT (Liu et al., 2014), and because Cyclin A-CDK2 
dependent phosphorylation of Cdh1 impairs its binding to the APC/C core complex, further 
restraining APC/C activity (Lukas et al., 1999). The inactivation of both AKT and CDK in 
late mitosis resets the system. Evaluating this model with computational and experimental 
analysis is an important future question. This model has potential implications regarding the 
mechanism by which cells arrest in response to growth factor withdrawal (Pardee, 1974).
We have also demonstrated a unique mechanism for regulating substrate ubiquitylation and 
degradation, namely, the phospho-dependent assembly of a CRL-type E3 ligase complex. 
We found that AKT phosphorylation of Cyclin F enhances its assembly into functional 
ligase complexes. However, the structural features in Cyclin F that increase binding to Skp1 
remain unclear. Dissecting the relative contributions of the two AKT phosphorylation sites 
to Skp1 binding remains an important question. Determining the structure of the Cyclin F-
Skp1 complex will shed light on the mechanisms of SCF assembly and their regulation of 
phosphorylation.
It has previously been established that phosphorylation, as well as other post-translational 
modifications of substrates, plays an important role in regulating ligase-substrate 
interactions. This places the point of regulation for SCF substrate ubiquitylation at the level 
of the substrate. However, there are alternative mechanisms that control substrate 
ubiquitylation for non-SCF E3 ligases. For example, for the APC/C, substrate modification 
is controlled at the ligase level, which is turned on or off through myriad mechanisms. One 
such mechanism regulates the ability of the APC/C substrate receptor Cdh1 to associate with 
the E3 via phosphorylation, thereby controlling substrate degradation. We show here that 
phosphorylation controls the assembly of SCF(Cyclin F) ligases. This raises the possibility 
that assembly and activation of additional SCF complexes is controlled in a similar fashion. 
Moreover, these data suggest the intriguing possibility that the global allocation of F-box 
proteins into competent E3 ligase complexes is dynamically controlled by phospho-signaling 
cascades. The conservation of phosphorylation sites at and nearby to the same site as T31 in 
other F-box proteins support this idea. We predict that coupling ligase assembly to signal 
transduction regulators that sense the physiological state of the cell could allow for the 
dynamic reorganization of the assembled E3 ligase repertoire.
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The G1/S boundary is a common target of oncogenic perturbation. For example, inactivating 
mutations in the retinoblastoma tumor suppressor are common in many cancers. Cdh1 is 
important in controlling G1, and loss of a single allele in mice can cause cancer (García-
Higuera et al., 2008). However, Cdh1 is neither mutated nor deleted in human malignancies. 
Thus, it remains unclear if Cdh1 is inactivated in human cancer. Our discovery that activated 
AKT can post-translationally repress Cdh1 suggests that cancers with activated AKT are 
likely to have reduced APC/C(Cdh1) activity at the G1/S boundary. This mechanism would 
obviate the need to genetically inactivate Cdh1, which increases DNA damage and could be 
cell lethal. Reports in flies, worms, and human cells have indicated that Cdh1 and the 
CDK4/6-RB pathway cooperate in controlling cell cycle entry (Binné et al., 2007; Buttitta et 
al., 2010; Fay et al., 2002; The et al., 2015). These observations, and our demonstration that 
AKT represses Cdh1, indicate a potential explanation for the synergy observed between 
PI3K and CDK4/6 inhibitors in models of breast cancer (Vora et al., 2014).
EXPERIMENTAL PROCEDURES
Mammalian cell culture and immunoblotting
HEK-293T, HCT-116, RPE1, HeLa and U2OS cells were obtained from ATCC, and grown 
in DMEM complete medium (Gibco) supplemented with 10% fetal bovine serum (Atlanta 
Biologicals). The small molecule inhibitors of AKT (AZD5363 and GSK-2141795) and 
PI3K (LY94002) were purchased from Selleckchem and added to cells for 6 hours at a final 
concentration of 10μM each. Prior to cycloheximide chase, 10μM AKT inhibitor 
(GSK-2141795) was added for 6 hours and chase and was performed in presence of the 
inhibitor.
Transfection experiments were performed in HEK-293T or HCT-116 cells unless otherwise 
stated. Cell lysis for immunoblot and SDS-PAGE is performed using standard techniques, as 
described in the supplemental experimental procedures.
Molecular biology
Cyclin F constructs were generated as mentioned previously (Choudhury et al., 2016). All 
genes were subcloned using PCR, and mutants generated using site directed mutagenesis 
were sequence verified. PCR amplification of DNA was performed using Hi fidelity DNA 
polymerase purchased from New England Biolabs or Agilent Inc. Myc tagged Cyclin F 
vectors were mutated using standard site directed mutation protocols. FLAG-Cyclin F 
truncation constructs were gift from Michele Pagano. The HA tagged version of HA-Myr-
AKT was a gift from Dr. Channing Der.
All siRNA transfection experiments were performed using RNAimax (Life Technologies). 
The oligonucleotide sequences for siRNA used in this study are detailed in the key resources 
table. The sequences for siRNAs are available in the supplemental experimental procedures.
Immuno-precipitation
Standard procedures of immuno-precipitation (IP) were used. Myc tagged Cyclin F WT or 
mutants in HEK 293T cells for 24 h. FLAG-tagged full length Cyclin F or truncated versions 
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were co-expressed Myr-HA AKT. Cells were dislodged by trypsinization, washed with PBS 
(DIFCO) and lysed in NETN for 30 min at 4°C with occasional vortexing. Cell debris were 
removed by centrifugation at 15,000 rpm for 15 min at 4°C. Anti-FLAG M2, anti-HA or 
anti-Myc beads (20 ml per IP, Sigma, Cat No F2426, E6779 and E6654 respectively) were 
equilibrated on a rotary shaker in lysis buffer. The clarified lysate was loaded on the beads 
and bound on rotary shaker for 4h to overnight at 4°C. The beads were washed with lysis 
buffer three times and then incubated with sample buffer (60 mM Tris pH 6.8, 2% SDS, 10% 
glycerol, 100 mM DTT and 0.1% Bromophenol Blue) at 70°C for 10 minutes. For 
purification of Myc-Cyclin FWT or Myc-Cyclin FAA used in in vitro kinase assays, mutant 
cells expressing these constructs were lysed in NETN buffer without phosphatase inhibitor, 
immunoprecipitated with anti-Myc beads, and eluted using 100 mM Glycine (pH 2.0). 
Eluents were neutralized with 1M Tris base to pH 7.5.
Endogenous Cyclin F IP was performed from extracts obtained from HEK-293T. Briefly, 
cells are lysed in NETN lysis buffer for 30 min at 4°C an d clarified using centrifugation. 
Lysates were mixed with 1μg of the Cyclin F polyclonal Rabbit antibody (sc-952) and 75μl 
of the equilibrated protein A/G beads. Control beads were prepared using normal Rabbit IgG 
(sc-2027). Lysate, antibody and bead slurry was incubated at 4°C in rotary agitator over 
night washed three times with NETN lysis buffer and eluted as above.
Mass spectrometry analysis
Samples were prepared from cell expressing Myc-Cyclin F with and without HA-Myr-
AKT1. Myc-Cyclin F was immunoprecipitated and subjected to SDS-PAGE and stained 
with coomassie. The bands corresponding to Cyclin F were excised and the proteins were 
reduced, alkylated, and in-gel digested with trypsin overnight at 37°C. The extracted 
peptides were enriched for phosphopeptides with IMAC as previously described (Chien et 
al., 2011). The bound peptides were eluted with 5% NH4OH from IMAC resin, then 
acidified, dried via vacuum centrifugation and stored at −80°C until analysis. Detailed 
description of LC-MS/MS is available in the supplemental experimental procedures.
In vitro kinase Assay
Myc-Cyclin F WT or AA protein was purified from 293T cells as described above and 
subject to in vitro kinase assay. GST-AKT1 was purchased form Sigma (Figure 1; Cat# SRP 
5001). Purified HA-Myr-AKT1 was isolated by pulldown from HEK293T cells 
(Supplemental Figure 1) as described (Liu et al., 2014). Kinase assays were performed in 
kinase buffer (25 mM MOPS, pH 7.2, 12.5 mM glycerol 2–phosphate, 25 mM MgCl2, 5 
mM EGTA, 2 mM EDTA and 0.25 mM DTT). The reaction was initiated with addition of 
ATP (1 μM) and performed at 30°C for 15–20 min and terminated by addition of sample 
buffer. The experiments in Figure 1 were carried out using recombinant GST-AKT1 and 
were analyzed using HA-Myr-Akt1 an AKT phospho motif antibody. The experiments in 
Supplemental Figure 1 were carried out using HA-Myr-AKT1 and analyzed using 
autoradiography for incorporation of [γ-32P] as previously described (Liu et al., 2014).
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In vivo ubiquitination and isolation of 6His-Ubiquitinated proteins
HEK-293T cells were transfected using Lipofectamine 2000 in 10 cm dishes and harvested 
in Phosphate Buffer Saline 24 h post-transfection. A FLAG-HIS ubiquitin construct (6-His-
Flag-Ub) was used for these studies, and was a generous gift from Dr. Philippe Soubeyran. 
80% of the cell suspension was lysed in buffer 1 [6 M Guanidine-HCl, 0.1 M 
Na2HPO4/NaH2PO4, 0.01 M Tris/HCl, pH 8.0, 15 mM imidazole and 10 mM β-
mercaptoethanol (βME)] and was used for pulldown of HIS-ubiquitin conjugated proteins. 
The remaining 20% of the cell suspension was used to prepare whole cell extracts and to 
analyze inputs by immunoblot. The lystates used for pulldown were sonicated to reduce 
viscosity, and loaded onto 50 μl of Ni2+-NTA resin (Thermo Scientific) pre-washed with 
buffer 1. Binding of the His tagged ubiquitin was performed at room temperature (RT) for 4 
h. The beads were successively washed with 750 μl of each of the following buffers: buffer 
1; buffer 2 (8 M Urea, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris/HCl, pH 8.0, 10 mM βME); 
buffer 3 (8 M Urea, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris/HCl, pH 6.3, 10mM βME) plus 
0.2% Triton X-100; buffer 3 and then buffer 3 plus 0.1% Triton X-100. After the last wash, 
bound proteins were eluted by incubating the beads in 50 μl of buffer 4 (200 mM imidazole, 
0.15 M Tris/HCl pH 6.7, 30% glycerol, 0.72 M βME, 5% SDS) for 20 min at RT. Eluates 
were analyzed by immunoblot.
Flow Cytometry and on plate EDU incorporation analysis
For flow cytometry analysis was in HCT116 cells were fixed in 70% ethanol and stained 
with propidium iodide using standard methods. Flow cytometry analysis was performed on 
CyAn ADP Analyzer. Non-transformed RPE1 cells were transfected using Lipofectamine 
3000 and serum starved for 24 hours to synchronize cells in G0/G1. Serum was added back 
to promote S-phase which was monitored by EdU (5-Ethynyl-2′-deoxyuridine; Sigma # 
T511285) incorporation. Cells were fixed on plates in 3.7% formaldehyde and washed in 
PBS prior to EdU labeling by azide-alkyne cycloaddition click chemistry. Click reactions are 
a total of 500 μl in PBS, and include: Alexa Fluor 488 Azide (final concentration of 1 μM), 
CuSO4 (final concentration of 1mM), ascorbic acid (final concentration of 100mM. The 
labeled cells were counter stained for DNA with 7-AAD or Hoechst. RPE-1 cells were 
plated in triplicate in 96-well plates at 5,000 cells/well and allowed to attach overnight. Cells 
were washed twice briefly in 1× PBS, synchronized in serum-free medium for 24 hr. G0 
synchronized cells were then simultaneously released into cell cycle with medium 
containing 10% fetal bovine serum in the presence of 10μM EdU and treated with increasing 
concentrations of the inhibitor (Afuresertib, MLN4924, Boterzomib, or Palbociclib) or 
vehicle (DMSO) for 18 hr. Cells were subsequently stained with the fluorescent azide as 
mentioned above. Images were captured on an EVOS™ FL Auto Imaging System (Life 
Technologies) and processed in ImageJ to obtain the percentage of EdU positive S-phase 
cells within the total number of cells in the field.
Homology based protein modeling
The HHpred server (http://toolkit.tuebingen.mpg.de/hhpred) was used to identify suitable 
structural templates for building a model of the Cyclin F/Skp1 complex (Soding, 2005). A 
model of the Cyclin F/Skp1 complex was built based on the structure of Fbxl3/Skp1 (PDB 
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ID: 4I6J) using Modeller 9.15 (Eswar et al., 2007). A rotamer was selected for the side chain 
of lysine 142 of Skp1 and a dihedral angle was selected for the phosphothreonine of Cyclin 
F that optimized the potential for an electrostatic interaction between the two residues.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• The cell cycle regulated F-box protein Cyclin F is an AKT substrate
• Phosphorylation by AKT increases Cyclin F stability
• Cyclin F phosphorylation promotes its assembly into E3 ligase complexes
• AKT phosphorylation of Cyclin F promotes the G1/S-phase transition
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Figure 1. Cyclin F is an AKT substrate
(A) Schematic of the reciprocal, cell cycle dependent regulation of Cyclin F and Cdh1 by 
ubiquitination.
(B) U2OS cells were synchronized in mitosis with nocodazole, isolated by “shake-off”, and 
analyzed by immunoblot after release into the cell cycle.
(C) Domain structure of human Cyclin F showing the position of Cyclin homology, F-box 
and PEST domains, and two putative AKT phosphorylation sites. Conserved AKT sites are 
shown as multiple sequence alignments. The AKT consensus motifs are shaded in blue.
(D) Myr-HA-AKT1 and Myc-Cyclin F were ectopically expressed in 293T cells and 
immunoprecipitated on anti-HA beads. Asterisk indicates nonspecific band resulting from 
IgG. Immunoblotted antigen is underlined to the right of blots.
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(E) Endogenous Cyclin F was immunoprecipitated from 293T cells and immunoblotted for 
AKT and Cyclin F.
(F) In vitro kinase assay was performed using recombinant GST-AKT1 and purified human 
Cyclin F. Phosphorylation was detected using an AKT phospho-motif specific antibody.
(G) Endogenous Cyclin F was immuno-precipitated from 293T cell extracts, washed 
stringently, and then probed with an AKT phospho-motif antibody. Prior to harvesting, cells 
were treated with an AKT inhibitor (afuresertib) or vehicle (DMSO) control.
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Figure 2. Cyclin F stability is regulated by the AKT activity
(A) Depletion of AKT1 or AKT2 in 293T cells with multiple siRNA reagents decreased 
Cyclin F abundance.
(B) Ectopic expression of AKT1 significantly increases the abundance of Myc-Cyclin F.
(C and D) Depletion of AKT1/2 decreases the half-life of endogenous Cyclin F in 293T 
cells.
(E and F) Pharmacological inhibition of AKT activity in HCT116 cells reduces the half-life 
of endogenous Cyclin F.
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(G and H) Overexpression of constitutively active AKT (HA-Myr-AKT1) increases the half-
life of ectopically expressed Myc-Cyclin F. In all immunoblot quantifications (above-right), 
blue indicates control and orange indicates experimental condition.
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Figure 3. SCF(Cyclin F) assembly is regulated by AKT phosphorylation
(A) Stability analysis of Myc-Cyclin FWT and Myc-Cyclin FAA was performed in 293T cells 
by cycloheximide chase, indicating that Cyclin FAA is unstable compared to Cyclin FWT.
(B) Quantification of immunoblots shown in panel A.
(C) Cyclin F and Skp1 homology modelling predicts that phosphorylation of T31 in Cyclin 
F will introduce an electrostatic interaction with lysine 142 in Skp1, leading to better 
docking. Stick representations highlight the positions of K142 in Skp1 and phospho-T31 in 
Cyclin F.
(D) Ectopic expression of AKT increases Cyclin F-Skp1 biding based on anti-Myc Cyclin F 
coIP from 293T cells.
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(E) Ectopic expression and immunoprecipitation of Myc-Cyclin FAA (T31A, S577A) or 
Myc-Cyclin FDD (T31D, S577D) in 293T cells leads to differential Skp1-Cul1-Cyclin F 
binding.
(F) Myc-Cyclin FWT and phospho-mutant versions were precipitated from 293T cells and 
analyzed by immunoblot.
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Figure 4. AKT promotes E3 ligase activity SCF(Cyclin F)
(A) Serum starvation and refeeding of HCT116 cells increases AKT activity and Cyclin F 
levels in a time-dependent manner.
(B) Pharmacological inhibition of PI3K or AKT kinases for six hours reduces Cyclin F 
protein levels in HeLa cells.
(C) The introduction of AKT1 stabilizes Cyclin F and promotes degradation of Cdh1. 
FLAG-Cdh1, Myr-HA-AKT1, and Myc-Cyclin F were co-expressed in various 
combinations.
(D) Myc-Cyclin F, FLAG-Cdh1, and 6HIS-ubiquitin were expressed in 293T cells, and 
ubiquitin conjugates were recovered on nickel agarose under denaturing conditions. 
Ubiquitylation of Cdh1 was analyzed by immunoblot. Cells were treated with MG-132 prior 
to harvesting and lysis.
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Figure 5. Cyclin F phosphorylation is required for G1/S progression
(A) Non-transformed RPE1 cells were synchronized in G0/G1 by serum withdrawal. After 
refeeding, entry in S-phase was monitored using EdU labeling.
(B) Depletion of Cyclin F with siRNA decreases S-phase entry.
(C) RPE1 cells were transfected with various versions of Cyclin F (WT, AA, DD) and then 
synchronized in G0/G1 as in panel A. Immunoblot of RPE1 cells overexpressing different 
Cyclin F mutants, prior to refeeding, is shown.
(D) After refeeding, cells were pulse labeled with EdU, fixed, and analyzed for S-phase 
entry. Representative images and DNA staining (top) of EdU positive cells (bottom) are 
shown.
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(E) The percent of nuclei that are EdU positive is shown (performed in triplicate, * p≤0.01; 
** p≤0.004; NS= not significant, p values were calculated using un-paired t-test). No serum 
control is shown in blue while the orange bar depicts 2% serum refeeding.
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